(Q37723328)

22 August 2017

1 reference

title

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents (English)

1 reference

22 August 2017

author

Christophe Le Tourneau

1

object named as

Christophe Le Tourneau

0 references

author name string

Véronique Diéras

2

1 reference

22 August 2017

Patricia Tresca

3

1 reference

22 August 2017

Wulfran Cacheux

4

1 reference

22 August 2017

Xavier Paoletti

5

1 reference

22 August 2017

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

5

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

65-72

1 reference

Phase I trial design: are new methodologies being put into practice?

22 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11523-010-0137-6

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

21 January 2018

1 reference

12 December 2020

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

1 reference

12 December 2020

Sequential continual reassessment method for two-dimensional dose finding

1 reference

12 December 2020

The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies

1 reference

12 December 2020

Challenges and pitfalls of combining targeted agents in phase I studies

1 reference

12 December 2020

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

12 December 2020

Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.

1 reference

12 December 2020

Dose selection in phase I studies: why we should always go for the top

1 reference

12 December 2020

There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture

1 reference

12 December 2020

Cancer phase I clinical trials: efficient dose escalation with overdose control.

1 reference

12 December 2020

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

12 December 2020

Dose escalation trial designs based on a molecularly targeted endpoint

1 reference

12 December 2020

Trends in the use and role of biomarkers in phase I oncology trials

1 reference

12 December 2020

Cardiovascular toxicity of molecularly targeted agents.

1 reference

12 December 2020

Dose escalation methods in phase I cancer clinical trials

1 reference

12 December 2020

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

12 December 2020

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

12 December 2020

An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations.

1 reference

12 December 2020

Economics of new oncology drug development

1 reference

12 December 2020

A parallel phase I/II clinical trial design for combination therapies.

1 reference

12 December 2020

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

12 December 2020

Patients' decision-making process regarding participation in phase I oncology research

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Skin toxicities of targeted therapies.

1 reference

12 December 2020

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

1 reference

12 December 2020

Phase I drug combination trial design: walking the tightrope

1 reference

12 December 2020

Dose‐Finding with Two Agents in Phase I Oncology Trials

1 reference

12 December 2020

Perceptions of cancer patients and their physicians involved in phase I trials

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

1 reference

12 December 2020

Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests

1 reference

12 December 2020

Pharmacologically guided phase I clinical trials based upon preclinical drug development

1 reference

12 December 2020

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

What is the right dose? The elusive optimal biologic dose in phase I clinical trials

1 reference

12 December 2020

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development

1 reference

12 December 2020

Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?

1 reference

12 December 2020

Translation of innovative designs into phase I trials

1 reference

12 December 2020

Dose-finding based on efficacy-toxicity trade-offs

1 reference

12 December 2020

Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents

1 reference

12 December 2020

Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.

1 reference

12 December 2020

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

12 December 2020

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

12 December 2020

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Continual reassessment method: a practical design for phase 1 clinical trials in cancer

1 reference

12 December 2020

Molecularly targeted oncology therapeutics and prolongation of the QT interval

1 reference

12 December 2020

Accelerated titration designs for phase I clinical trials in oncology

1 reference

12 December 2020

Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.

1 reference

12 December 2020

Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

1 reference

12 December 2020

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

1 reference

12 December 2020

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma

1 reference

12 December 2020

Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy

1 reference

12 December 2020

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

1 reference

12 December 2020

Phase I clinical trial design in cancer drug development

1 reference

12 December 2020

Gastrointestinal toxicities of novel agents in cancer therapy.

1 reference

12 December 2020

Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials

1 reference

12 December 2020

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

1 reference

12 December 2020

Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck

1 reference

12 December 2020

An adaptive dose-finding design incorporating both toxicity and efficacy.

1 reference

12 December 2020

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

1 reference

12 December 2020

A latent contingency table approach to dose finding for combinations of two agents

1 reference

12 December 2020

10.1007/S11523-010-0137-6

Identifiers

DOI

1 reference

22 August 2017

1 reference